Stempharm
1 known investors
Stem Pharm develops human neural organoids featuring microglia and chemically-defined synthetic hydrogel substrates for in vitro modeling of neuroinflammatory diseases. It offers drug discovery services and partnerships covering neurologic disease modeling, target discovery, phenotypic screening, and neurotoxicity assessment.
BiotechDeep TechHealthtech
Investors Β· 1
Frequently asked questions
- What does Stempharm do?
- Stem Pharm develops human neural organoids featuring microglia and chemically-defined synthetic hydrogel substrates for in vitro modeling of neuroinflammatory diseases. It offers drug discovery services and partnerships covering neurologic disease modeling, target discovery, phenotypic screening, and neurotoxicity assessment.
- Who are Stempharm's investors?
- Stempharm's investors include First In Ventures.